State of Peptides 2026
A data-driven snapshot of the peptide landscape: 156 compounds analyzed across 10 therapeutic categories, 5 legal classifications, and 6routes of administration. All statistics computed from PeptaHub’s structured database.
The peptide regulatory environment is in flux. The RFK Jr. reclassification initiative has placed 10 peptides in a pending status, while the FDA continues active enforcement against gray-market vendors. Here is how our 156-compound database breaks down by legal classification:
Subcutaneous injection remains the dominant route, but 75 peptides (48%) support multiple routes. The oral peptide pipeline (orforglipron, oral semaglutide) represents a significant shift toward patient-friendly administration.
10 peptides are currently under FDA reclassification review as part of the RFK Jr. initiative. If reclassified, these compounds could return to legal compounding status through licensed 503A/503B pharmacies.
All statistics on this page are computed directly from PeptaHub’s structured peptide database of 156 published profiles. Category counts include subcategory assignments (a peptide can appear in multiple categories). Review counts reflect aggregated community interest signals. Legal status classifications follow FDA enforcement actions and published guidance as of April 2026.
This data is free to cite and reference. If you use these statistics in research, reporting, or content, please link back to peptahub.com/state-of-peptides-2026 as the source.
Full Peptide Directory
Browse all 156 profiles with mechanisms, dosing, and evidence.
Interactive Tools
Dosing calculator, stack compatibility checker, and peptide finder quiz.
Head-to-Head Comparisons
61 side-by-side analyses of mechanism, dosing, and evidence.
FDA Timeline
Complete timeline of FDA actions, vendor shutdowns, and reclassification.
156 compounds. 10 categories. 5 legal classifications. One reference.